Goldman Sachs’ investment arm agrees €2bn deal for drugmaker Synthon
Goldman Sachs Asset Management has agreed a more than €2bn deal to acquire drugmaker Synthon from BC Partners, according to people familiar with the matter, as it hopes to capitalise on demand for off ...
Goldman Sachs Asset Management nears deal to buy Synthon, FT reports
Goldman Sachs Asset Management (GS) is nearing a more than EUR 2B deal to buy drugmaker Synthon from BC Partners, people familiar tell the ...
PE Hub6h
BC Partners agrees to sell majority stake in Synthon to Goldman Sachs Alternatives
BC Partners has agreed to sell its majority stake in Synthon to Goldman Sachs Alternatives. Synthon is an international pharmaceutical company, with a platform specialized in developing, manufacturing ...
Goldman Unit Buys €2 Billion Drugmaker Synthon From BC Partners
Goldman Sachs Group Inc.’s alternative investment arm has agreed to buy a majority stake in Dutch generic drugmaker Synthon from BC Partners.
NL Times11h
Goldman Sachs set to pay €2 billion for Dutch pharma firm Synthon International
Goldman Sachs’ asset arm is in the process of acquiring the Dutch pharmaceutical company Synthon International for 2 billion ...
Yahoo Finance5h
Companion Diagnostic Collaboration and Licensing Deals Directory 2024: Comprehensive Listing of 530 Companion Diagnostic Deals Announced Since 2010
Dublin, Dec. 16, 2024 (GLOBE NEWSWIRE) -- The "Companion Diagnostic Collaboration and Licensing Deals 2010-2024" report has been added to ResearchAndMarkets.com's offering. Companion Diagnostic ...